MAINZ BIOMED N.V.

QUCY Nasdaq CIK: 0001874252

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation Netherlands
Business Address ROBERT KOCH STRASSE 50, MAINZ, 2M, 55129
Mailing Address ROBERT KOCH STRASSE 50, MAINZ, 2M, 55129
Phone 49 6131 5542860
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025

-$16.21M
Net Income
$13.50M
Total Assets
$7.50M
Total Liabilities
$6.00M
Stockholders' Equity
$-2.70
EPS

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 31, 2026 View on SEC
8-K Current report of material events March 25, 2026 View on SEC
DEF 14A Definitive proxy statement March 25, 2026 View on SEC
8-K Current report of material events March 17, 2026 View on SEC
8-K Current report of material events March 11, 2026 View on SEC
3 Initial insider ownership report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report February 19, 2026 View on SEC
4 Insider stock transaction report February 19, 2026 View on SEC
3 Initial insider ownership report February 19, 2026 View on SEC

Annual Reports

10-K March 31, 2026
  • Strategic pivot from biotech to post-quantum cybersecurity under new name 'Quantum Cyber N.V.'
  • Divestiture of ColoAlert business for $2.5 million to address cash constraints
View Analysis

Material Events

8-K Financial Distress March 25, 2026
High Impact
  • ColoAlert® cancer screening test serves as the primary growth driver.
  • Company has a 180-day window until September 16, 2026, to regain compliance.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.